Abacavir Oral Solution |
Ziagen Solution |
Clinical Trial: HIV Study Of GW433908 Versus Kaletra, Both With Abacavir/lamivudine In Therapy-Naive Patients
This study is no longer recruiting patients.
|
Purpose
This randomized, multicenter study will compare the safety and efficacy of Lexiva plus ritonavir versus Kaletra (Lopinavir/ritonavir) over 48 weeks in ART (anti-retroviral therapy)-naive HIV-1 infected subjects while utilizing the Abacavir/lamivudine (ABC/3TC) FDC (fixed-dose combination tablet) as a NRTI (nucleoside reverse transcriptase inhibitor) backbone. This clinical research study evaluates the safety and efficacy (how well it works) of marketed HIV drugs [PI (protease inhibitor) plus NRTIs] given to HIV-infected patients who have not received prior therapy. All subjects will be screened and monitored at 12 scheduled clinic visits over a 48-week period. Abnormal laboratory values or certain side effects may require additional clinic visits over the course of the study.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| HIV Infections | Drug: Lexiva (GW433908) Drug: Ritonavir Drug: Kaletra Drug: Epivir Drug: Ziagen | Phase III |
MedlinePlus related topics: AIDS
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Eligibility
Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both
Criteria
Inclusion Criteria:
- Persons with HIV-1 infections who have not started any antiretroviral medication regimen
- HIV-1 RNA (viral load) >1,000 c/mL
- Participants must be able to provide informed consent
- Have not received more than 14 days of prior treatment with HIV drugs
- Meet laboratory test criteria
- Women must abstain from sexual intercourse or use acceptable contraception
- Must be able to take study medications as directed and complete all study visits and evaluations during the 48-week study
Exclusion Criteria:
- Enrolled in other HIV treatment studies
- Pregnant or breastfeeding
Other protocol inclusion or exclusion criteria to be evaluated by the research physicians.
Location Information
Alabama
Birmingham, Alabama, 35233, United States
Arizona
Phoenix, Arizona, 85006, United States
California
Beverly Hills, California, 90211, United States
San Diego, California, 92106, United States
Newport Beach, California, 92663, United States
San Francisco, California, 94115, United States
Berkley, California, 94705, United States
Sacramento, California, 95825, United States
Colorado
Denver, Colorado, 80220, United States
District of Columbia
Washington, District of Columbia, 20036, United States
Washington, District of Columbia, 20037, United States
Washington, District of Columbia, 20057, United States
Florida
Altamonte Springs, Florida, 32701, United States
Pembroke Pines, Florida, 33024, United States
Miami, Florida, 33101, United States
Fort Lauderdale, Florida, 33308, United States
Tampa, Florida, 33602, United States
Tampa, Florida, 33607, United States
Tampa, Florida, 33614, United States
Bradenton, Florida, 34205, United States
Georgia
Atlanta, Georgia, 30308, United States
Atlanta, Georgia, 30339, United States
Illinois
Maywood, Illinois, 60153, United States
Chicago, Illinois, 60612, United States
Chicago, Illinois, 60612, United States
Chicago, Illinois, 60613, United States
Chicago, Illinois, 60657, United States
Indiana
Indianapolis, Indiana, 46202, United States
Indianapolis, Indiana, 46202, United States
Kentucky
Lexington, Kentucky, 40536, United States
Maine
Portland, Maine, 04102, United States
Maryland
Baltimore, Maryland, 21201, United States
Massachusetts
Boston, Massachusetts, 02115, United States
Boston, Massachusetts, 02118, United States
Minnesota
Minneapolis, Minnesota, 55404, United States
Mississippi
Jackson, Mississippi, 39202, United States
Missouri
St. Louis, Missouri, 63108, United States
New Jersey
Newark, New Jersey, 07103, United States
Voorhees, New Jersey, 08043, United States
Somers Point, New Jersey, 08244, United States
Hillsborough, New Jersey, 08844, United States
New York
New York, New York, 10014, United States
Bronx, New York, 10461, United States
Bronx, New York, 10468, United States
Stony Brook, New York, 11794, United States
Rochester, New York, 14604, United States
North Carolina
Chapel Hill, North Carolina, 27516, United States
Durham, North Carolina, 27710, United States
Greenville, North Carolina, 27858, United States
Charlotte, North Carolina, 28209, United States
Ohio
Toledo, Ohio, 43614, United States
Oklahoma
Oklahoma City, Oklahoma, 73104, United States
Pennsylvania
Philadelphia, Pennsylvania, 19102, United States
Philadelphia, Pennsylvania, 19107, United States
Rhode Island
Providence, Rhode Island, 02906, United States
South Carolina
Columbia, South Carolina, 29206, United States
Tennessee
Knoxville, Tennessee, 37920, United States
Memphis, Tennessee, 38163, United States
Texas
Dallas, Texas, 75208, United States
Dallas, Texas, 75246, United States
Dallas, Texas, 75246, United States
Fort Worth, Texas, 76104, United States
Houston, Texas, 77004, United States
Houston, Texas, 77030, United States
Virginia
Charlottesville, Virginia, 22908, United States
Hampton, Virginia, 23666, United States
Lynchburg, Virginia, 24501, United States
Washington
Seattle, Washington, 98111, United States
Seattle, Washington, 98122, United States
Spokane, Washington, 99204, United States
Wisconsin
Milwaukee, Wisconsin, 53226, United States
Austria
Vienna, A-1090, Austria
Vienna, A-1090, Austria
Vienna, A-1140, Austria
Belgium
Luxembourg, 1210, Belgium
Leuven, 3000, Belgium
LIEGE, 4000, Belgium
Charleroi, 6000, Belgium
Gent, 9000, Belgium
Canada, Alberta
Calgary, Alberta, T2P 1H9, Canada
Canada, Ontario
Ottawa, Ontario, K1N 6N5, Canada
Toronto, Ontario, M4N 3M5, Canada
Toronto, Ontario, M4T 3A7, Canada
Toronto, Ontario, M5B 1W8, Canada
Toronto, Ontario, M5G 2N2, Canada
Canada, Quebec
Montreal, Quebec, H2L 4P9, Canada
Montreal, Quebec, H2L 5B1, Canada
Montreal, Quebec, H2L 5B1, Canada
France
Bordeaux Cedex, 33076, France
Lyon cedex 02, 69288, France
Lyon Cedex 03, 69437, France
Paris, 75010, France
Paris, 75018, France
Paris Cedex 10, 75475, France
Paris Cedex13, 75651, France
Paris Cedex 14, 75679, France
Paris Cedex 20, 75970, France
Le Kremlin Bicetre Cedex, 94275, France
Germany
Berlin, 13353, Germany
Hamburg, 20095, Germany
Hamburg, 20099, Germany
Germany, Bayern
Muenchen, Bayern, 80331, Germany
Fuerth, Bayern, 90762, Germany
Germany, Hessen
Frankfurt, Hessen, 60590, Germany
Germany, Niedersachsen
Hannover, Niedersachsen, 30159, Germany
Germany, Nordrhein-Westfalen
Dortmund, Nordrhein-Westfalen, 44137, Germany
Italy
Milano, 20157, Italy
Milano, 20157, Italy
Busto Arsizio, 21052, Italy
Latvia
Riga, LV1006, Latvia
Poland
Warszawa, 01 201, Poland
Portugal
Lisboa, 1069-166, Portugal
Lisboa, 1150, Portugal
Lisboa, 1649-035, Portugal
Cascais, 2750, Portugal
Switzerland
Munchenstein, 4142, Switzerland
Lugano, 6900, Switzerland
St. Gallen, 9007, Switzerland
Zurich, CH-8091, Switzerland
More Information
Record last reviewed: January 2005
Last Updated: January 18, 2005
Record first received: June 17, 2004
ClinicalTrials.gov Identifier: NCT00085943
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


